Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Incyte Corp Market Cap
Based on ratings from 26 stock analysts, the Incyte Corp stock price is expected to increase by 3.14% in 12 months. This is calculated by using the average 12-month stock price forecast for Incyte Corp. The lowest target is $52 and the highest is $97. Please note analyst price targets are not guaranteed and could be missed completely.
Incyte Corp has a total of 26 Wall St Analyst ratings. There are 12 buy ratings, 13 ratings, and 1 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Incyte Corp will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of INCY.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Brian Abrahams RBC Capital | Sector Perform | $74 | Maintains | Nov 19, 2024 |
| Eric Schmidt Cantor Fitzgerald | Neutral | Reiterates | Nov 19, 2024 | |
| Brian Abrahams RBC Capital | Sector Perform | $80 | Maintains | Nov 14, 2024 |
| Vikram Purohit Morgan Stanley | Equal-Weight | $69 | Maintains | Oct 30, 2024 |
| Tazeen Ahmad B of A Securities | Buy | $90 | Upgrade | Oct 30, 2024 |
| Jay Olson Oppenheimer | Outperform | $82 | Maintains | Oct 30, 2024 |
| Evan Seigerman BMO Capital | Underperform | $52 | Reiterates | Oct 30, 2024 |
| David Lebowitz Citigroup | Buy | $97 | Maintains | Oct 30, 2024 |
| Derek Archila Wells Fargo | Equal-Weight | $68 | Maintains | Oct 30, 2024 |
| Salveen Richter Goldman Sachs | Neutral | $70 | Maintains | Oct 30, 2024 |
| Jessica Fye JP Morgan | Neutral | $71 | Maintains | Oct 30, 2024 |
| Brian Abrahams RBC Capital | Sector Perform | $72 | Maintains | Oct 30, 2024 |
| Jessica Fye JP Morgan | Neutral | $65 | Maintains | Oct 23, 2024 |
| Derek Archila Wells Fargo | Equal-Weight | $62 | Maintains | Oct 10, 2024 |
| Andy Chen Wolfe Research | Outperform | Initiates | Oct 1, 2024 | |
| Srikripa Devarakonda Truist Securities | Hold | $74 | Downgrade | Sep 18, 2024 |
| Reni Benjamin JMP Securities | Market Perform | Reiterates | Sep 17, 2024 | |
| Michael Schmidt Guggenheim | Buy | $92 | Maintains | Sep 16, 2024 |
| Eric Schmidt Cantor Fitzgerald | Neutral | Reiterates | Sep 16, 2024 | |
| Tazeen Ahmad B of A Securities | Neutral | $68 | Maintains | Sep 16, 2024 |
When did it IPO
1993
Staff Count
2,524
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Herve Hoppenot
Market Cap
$14.63B
In 2023, INCY generated $3.70B in revenue, which was a increase of 8.87% from the previous year. This can be seen as a signal that INCY's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 05 Dec 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Levi & Korsinsky is investigating Incyte Corporation (NASDAQ: INCY) for potential federal securities law violations following its decision to pause enrollment in a Phase 2 study due to toxicology findings.
Why It Matters - The investigation into Incyte Corporation for potential securities law violations and the pause in its drug trial could significantly impact stock performance and investor confidence.
Fri, 06 Dec 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Levi & Korsinsky has launched an investigation into Incyte Corporation (NASDAQ: INCY) for potential federal securities law violations after the company paused enrollment in a drug study due to toxicity concerns.
Why It Matters - The investigation into Incyte Corporation signals potential legal risks and regulatory scrutiny, which may impact stock performance and investor confidence in the company.
Fri, 06 Dec 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Incyte has reported inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4).
Why It Matters - Incyte's inducement grants signal potential new hiring or retention efforts, which could impact future growth and operational performance, influencing investor sentiment and stock valuation.
Mon, 02 Dec 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Levi & Korsinsky is investigating Incyte Corporation (NASDAQ: INCY) for potential federal securities law violations after it paused enrollment in a Phase 2 study for its drug INCB000262 due to toxicology concerns.
Why It Matters - The investigation into Incyte Corporation and the paused drug trial raise concerns about potential regulatory issues and financial implications, which could impact stock performance and investor confidence.
Tue, 03 Dec 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Levi & Korsinsky is investigating Incyte Corporation (NASDAQ: INCY) for potential federal securities law violations following the pause of enrollment in a Phase 2 study of its drug INCB000262 due to toxicology concerns.
Why It Matters - The investigation into Incyte Corporation may indicate potential legal issues and regulatory scrutiny, raising concerns about the company's future performance and stock viability.
Wed, 04 Dec 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Levi & Korsinsky is investigating Incyte Corporation (NASDAQ: INCY) for potential federal securities law violations after the company paused enrollment in a Phase 2 study due to toxicology concerns.
Why It Matters - The investigation into Incyte may indicate potential legal issues and regulatory scrutiny, impacting stock performance and investor confidence in the company's future prospects.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
